Han-Mo Koo Seminar Series

Speaker: Bruce H. Littman, M.D.
VAI Host:  Webb , Craig, Ph.D.
Speaker Affiliation: Translational Medicine Associates, LLC
Speaker Title: President
Date: September 10, 2008
Time: 12:00 PM to 1:00 PM
Location: Van Andel Institute - Tomatis Auditorium

Following post-graduate training as an internist, rheumatologist and immunologist at Tufts New England Medical Center, Harvard's Robert B. Brigham Hospital and the National Cancer Institute, N.I.H. in Bethesda, MD, Bruce joined the faculty at the Medical College of Virginia, Virginia Commonwealth University. During 13 years at M.C.V. his laboratory research was on cytokine regulation of complement production and the mode of action of RA DMARDs. His translational and clinical research interests were rheumatoid arthritis pathogenesis and treatment.

After joining Pfizer's first Experimental Medicine group in 1989, Bruce's main focus became translational pharmacology, biomarker driven development decisions and exploratory clinical development across multiple therapeutic areas. He became the head of the Experimental Medicine group at legacy Pfizer and later was instrumental in starting Pfizer's Clinical Pharmacogenomics group and Pfizer's first biomarker laboratory. He played a key role in implementing important organizational changes through two major acquisitions.

As Vice President, Global Head of Translational Medicine, he established Pfizer's Global Translational Medicine organization with groups in each of eleven therapeutic areas. Translational Medicine worked to improve Phase 2 survival through biomarker development for early validation of drug targets; demonstration of desired pharmacological activity in Phase 1; and development of clinical methods and biomarkers to advance the development of Pfizer products. In addition Bruce had other global responsibilities as a member of the Clinical Quantitative and Innovative Medicine Leadership Team, Scientific Excellence Board and CAN Quality Guidelines Committee. Bruce is also Co-Chair of the Inflammation and Immunity Steering Committee of The Biomarker Consortium (Foundation for the NIH) and Co-Chair of the Predictive Efficacy Models Working Group, a PISC PhRMA initiative.

After 19 years at Pfizer, in December 2007 Bruce retired and started an independent consulting company, Translational Medicine Associates, LLC (TMA). Bruce also remains co-chair for the Inflammation and Immunity Steering Committee of The Biomarker Consortium (Foundation for the NIH).

Through TMA, Bruce serves customers in the areas of translational research, early clinical development planning and execution, risk assessment for early biotech and drug investment opportunities and biomarker development. In addition TMA helps guide biotech and translational research companies through Bruce's membership on boards of directors. TMA is also able to network with many experts in these and related areas of translational research, biomarker development, pharmaceutical sciences and clinicians in multiple therapeutic areas.I

n person attendance.

Van Andel Research Institute
Tomatis Auditorium
333 Bostwick Ave., N.E.
Grand Rapids, Michigan
49503

Online viewing.

Via webcast* at http://media.vai.org/vaichannel2
Windows Media Player version 9 or above and at least 300Kbps of Internet bandwidth will be required.

*Participants viewing this webcast are not currently eligible for CME Accreditation; however, the Michigan State Medical Society is currently reviewing this process

“This activity has been planned and implemented in accordance with the Essential Areas and policies of the Michigan State Medical Society Committee on CME Accreditation through the joint sponsorship of the Grand Rapids Medical Education & Research Center for Health Professions and the Van Andel Research Institute. The Grand Rapids Medical Education & Research Center for Health Professions is accredited by the Michigan State Medical Society Committee on CME Accreditation to provide continuing medical education for physicians. The Grand Rapids Medical Education & Research Center for Health Professions designates this educational activity for a maximum of one Category 1 credit toward the AMA Physician’s Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.”

For more information please contact Laura Holman at (616) 234-5749